Parkinson's disease (PD) is a complex neurodegenerative illness associated with the loss or damage to neurons of the dopaminergic system in the brain. Few therapeutic approaches and considerable side effects of conventional drugs necessitate a new therapeutic agent to treat patients with PD. Rhaponticin is a natural hydroxystilbene, found in herbal plants such as Rheum rhaponticum, and known to have desirable biological activity including anti‐inflammatory properties. However, the neuroinflammation on rhaponticin levels has only been investigated partially so far. So, the current study explored whether rhaponticin could ameliorate the pathophysiology observed in both the in vitro microglial BV‐2 cells and the in vivo (1‐methyl‐4‐phenyl‐1,2,3,5‐tetrahydropyridine [MPTP])‐mediated PD model. The results show rhaponticin significantly attenuated lipopolysaccharide (LPS)‐mediated microglial activation by suppressing nitric oxide synthase in conjunction with abridged reactive oxygen species production together with proinflammatory mediator reduction. In vivo rhaponticin treatment improves motor impairments as well as the loss of dopaminergic neurons in MPTP‐treated mice possibly through suppression via mediators of inflammation. Taken together, these results offer evidence that rhaponticin exerts anti‐inflammatory effects and neuroprotection in an LPS‐induced microglial model and the MPTP‐induced mouse models of PD.

中文翻译：

---

雷帕霉素对帕金森氏病的神经保护作用：体外BV-2模型和体内MPTP诱导的小鼠模型的见解。

帕金森氏病（PD）是一种复杂的神经退行性疾病，与大脑中多巴胺能系统神经元的丧失或损害有关。常规药物很少有治疗方法和相当大的副作用，因此需要一种新的治疗剂来治疗PD患者。Rhaponticin是天然羟基二苯乙烯，见于大黄（Rheum rhaponticum）等草药植物中，并具有理想的生物学活性，包括抗炎特性。然而，到目前为止，仅对Rhaponticin水平的神经炎症进行了部分研究。因此，当前的研究探讨了葡萄红素能否改善在体外小胶质BV-2细胞和体内（1-甲基-4-苯基-1，2，3，5-四氢吡啶[MPTP]）中观察到的病理生理。介导的PD模型。结果表明，Rhapponticin通过抑制一氧化氮合酶，减少的活性氧生成以及促炎介质的减少，显着减弱了脂多糖（LPS）介导的小胶质细胞的激活。体内黄连蛋白的治疗可以改善MPTP处理的小鼠的运动障碍以及多巴胺能神经元的损失，这可能是通过炎症介质的抑制来实现的。